GLP-1 receptor agonists demonstrate anti-inflammatory and immunomodulatory properties that extend beyond their established metabolic benefits, with early clinical evidence showing improvements in psoriasis severity scores and hidradenitis suppurativa symptoms. Small studies report reduced Psoriasis Area and Severity Index scores and fewer wound complications, suggesting both direct immune effects and indirect benefits from weight loss and reduced systemic inflammation. This represents a potentially significant expansion of GLP-1 therapeutics beyond diabetes and obesity management into autoimmune dermatology. The anti-inflammatory mechanism aligns with growing evidence that GLP-1 receptors exist throughout immune tissues, not just pancreatic cells. However, the clinical evidence remains preliminary, consisting mainly of case reports and small cohorts with significant confounding variables including concurrent diabetes treatments and obesity. The dermatologic side effect profile also requires careful consideration, including potential drug eruptions, alopecia, and acne. While promising, this application requires robust randomized controlled trials to establish efficacy and safety profiles. The finding hints at broader anti-inflammatory applications for GLP-1 drugs across multiple organ systems, potentially reshaping how we view these medications from metabolic tools to systemic anti-inflammatory agents.